ArticleJAC-antimicrobial resistance2026
Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: real-world experience with therapeutic drug monitoring.
Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oritavancin is a long-acting semisynthetic lipoglycopeptide with potent activity against a broad range of Gram-positive pathogens. Its multimodal mechanism of action and prolonged terminal half-life allow for extended dosing intervals, making it an off-label option for invasive infections requiring long-term antimicrobial exposure. However, evidence supporting its use in infective endocarditis and cardiac device-related infections remain limited. Methods: We performed a retrospective multicentre observational study including adult patients treated with multidose oritavancin for infective endocarditis and cardiac device-related infections between 2020 and 2025. Oritavancin was administered as consolidation or as long-term suppressive therapy. Demographic, clinical, microbiological, pharmacological, and outcome data were collected. Therapeutic drug monitoring was performed, and pre-dose plasma concentrations were analysed. Clinical outcomes included clinical cure, microbiological failure, adverse events, and 30- and 90-day all-cause mortality. Results: Nine patients were included. Oritavancin was mainly administered at 1200 mg per dose, with a median dosing interval of 10 days. Clinical success was achieved in 6/9 patients (66.7%). One patient discontinued therapy due to infusion-related adverse events, and two experienced microbiological failure, both in left ventricular assist device-related infections. No 30- or 90-day mortality was observed. TDM, when performed, demonstrated persistent pre-dose plasma concentrations over several weeks, with marked interindividual variability across patients and intra-individual temporal changes over time, including drug accumulation in some cases. Conclusion: Multidose oritavancin appears to be a promising consolidation or suppressive strategy in selected patients with complex Gram-positive endovascular infections. Prospective studies are needed to define optimal dosing regimens and the role of TDM in this setting.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.